Comparative Pharmacology
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PREVACID.
OMEPRAZOLE MAGNESIUM vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
20 mg orally once daily for 4-8 weeks; for erosive esophagitis 20-40 mg orally once daily for 4-8 weeks; maintenance: 10-20 mg orally once daily; for Helicobacter pylori eradication: 20 mg orally twice daily for 10-14 days in combination with antibiotics.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (fast metabolizers); 2-3 hours (slow metabolizers); clinical context: prolonged in hepatic impairment, no significant accumulation with once-daily dosing due to irreversible inhibition of H+/K+-ATPase.
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Renal: 77% as metabolites; biliary/fecal: 16.7% as metabolites; active drug not excreted unchanged.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor